BioCentury
ARTICLE | Company News

Teva names Hayden CSO

May 9, 2012 1:24 AM UTC

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) hired Michael Hayden as CSO and president of global R&D. Hayden is currently a professor of medical genetics at the University of British Columbia and is Canada Research Chair in Human Genetics and Molecular Medicine. He has founded three biotechs: cancer company NeuroVir, which was acquired by MediGene AG (Xetra:MDG) in 2000; autoimmune company Aspreva Pharmaceuticals, which was acquired by Galenica Ltd. (SIX:GALN) in 2007; and neurology and endocrine/metabolic company Xenon Pharmaceuticals Inc. (Burnaby, B.C.). ...